PH26256A - Oxaspiro [2,5] octane derivative - Google Patents

Oxaspiro [2,5] octane derivative Download PDF

Info

Publication number
PH26256A
PH26256A PH39029A PH39029A PH26256A PH 26256 A PH26256 A PH 26256A PH 39029 A PH39029 A PH 39029A PH 39029 A PH39029 A PH 39029A PH 26256 A PH26256 A PH 26256A
Authority
PH
Philippines
Prior art keywords
alkyl
methyl
alkylcarbamoyl
hydroxy
oxaspiro
Prior art date
Application number
PH39029A
Other languages
English (en)
Inventor
Teruo Oku
Chiyoshi Kasahara
Takehiko Ohkawa
Masashi Hashimoto
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888819258A external-priority patent/GB8819258D0/en
Priority claimed from GB888819256A external-priority patent/GB8819256D0/en
Priority claimed from GB898908029A external-priority patent/GB8908029D0/en
Priority claimed from GB898909794A external-priority patent/GB8909794D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of PH26256A publication Critical patent/PH26256A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/34—Compounds containing oxirane rings with hydrocarbon radicals, substituted by sulphur, selenium or tellurium atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Dental Preparations (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Cereal-Derived Products (AREA)
PH39029A 1988-08-12 1989-08-01 Oxaspiro [2,5] octane derivative PH26256A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB888819258A GB8819258D0 (en) 1988-08-12 1988-08-12 Oxaspiro(2 5)octane compound
GB888819256A GB8819256D0 (en) 1988-08-12 1988-08-12 Oxaspiro(2 5)octane derivative
GB898908029A GB8908029D0 (en) 1989-04-10 1989-04-10 Oxaspriro(2,5)octane derivative
GB898909794A GB8909794D0 (en) 1989-04-28 1989-04-28 Cyclohexane derivative

Publications (1)

Publication Number Publication Date
PH26256A true PH26256A (en) 1992-04-01

Family

ID=27450157

Family Applications (1)

Application Number Title Priority Date Filing Date
PH39029A PH26256A (en) 1988-08-12 1989-08-01 Oxaspiro [2,5] octane derivative

Country Status (18)

Country Link
US (2) US5789405A (es)
EP (1) EP0354787B1 (es)
JP (2) JP2773275B2 (es)
KR (1) KR0130765B1 (es)
CN (1) CN1051703C (es)
AT (1) ATE118490T1 (es)
AU (1) AU632056B2 (es)
CA (1) CA1340291C (es)
DE (1) DE68921114T2 (es)
DK (1) DK171987B1 (es)
ES (1) ES2067546T3 (es)
FI (1) FI97805C (es)
GR (1) GR3015382T3 (es)
HU (1) HU211569A9 (es)
IE (1) IE66923B1 (es)
IL (1) IL91250A (es)
NO (1) NO173236C (es)
PH (1) PH26256A (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
JPH0660095B2 (ja) * 1988-09-01 1994-08-10 武田薬品工業株式会社 血管新生阻害剤
JPH0660168B2 (ja) * 1988-09-01 1994-08-10 武田薬品工業株式会社 ０―置換フマギロール誘導体
EP0682020A1 (en) * 1988-09-01 1995-11-15 Takeda Chemical Industries, Ltd. Fumagillol derivatives useful as angiogenesis inhibitors
ATE87623T1 (de) * 1989-03-06 1993-04-15 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (es) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
WO1993005777A1 (fr) * 1991-09-18 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation transoculaire
EP0602586B1 (en) * 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stable pharmaceutical composition of fumagillol derivatives
US5710148A (en) * 1995-03-06 1998-01-20 Senju Pharmaceuticals Co., Ltd. Corneal opacification inhibitory composition
FR2733499B1 (fr) * 1995-04-27 1997-05-30 Adir Nouvelles tetrahydropyrano(3,2-d)oxazolones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2733498B1 (fr) * 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5719167A (en) * 1995-08-07 1998-02-17 Alcon Laboratories, Inc. Angiostatic compounds
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
CA2234401A1 (en) * 1995-10-11 1997-04-17 Fujisawa Pharmaceutical Co., Ltd. Vascular permeation inhibitor
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
WO1999061432A1 (en) * 1998-05-12 1999-12-02 Biochem Pharma Inc. Fumagillin analogs and their use as angiogenesis inhibitors
KR100357541B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
AU3947902A (en) * 2000-11-01 2002-06-03 Praecis Pharm Inc Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1699812A2 (en) * 2003-12-29 2006-09-13 Praecis Pharmaceuticals Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
WO2007087330A2 (en) * 2006-01-24 2007-08-02 Goss International Americas, Inc. Signature hopper with lap straightening device
BRPI0820229A2 (pt) * 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
CA2731020A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
AU2010254013A1 (en) 2009-05-28 2011-11-24 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
MX337575B (es) 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
JP5827239B2 (ja) 2010-01-08 2015-12-02 ザフゲン，インコーポレイテッド フマギロール型化合物並びにその製造方法及び使用方法
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
AU2011281037B2 (en) 2010-07-22 2014-11-27 Zafgen, Inc. Tricyclic compounds and methods of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
AU2011336785A1 (en) 2010-11-29 2013-06-20 Zafgen, Inc Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
KR101875988B1 (ko) 2011-03-08 2018-07-06 자프겐 인크. 옥사스피로[2.5]옥탄 유도체 및 유사체
SG194812A1 (en) 2011-05-06 2013-12-30 Zafgen Inc Partially saturated tricyclic compounds and methods of making and using same
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
WO2013169727A1 (en) 2012-05-07 2013-11-14 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
KR20150079952A (ko) 2012-11-05 2015-07-08 자프겐 인크. 트리시클릭 화합물 및 그의 제조 및 사용 방법
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
ES2754397T3 (es) 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
AU2018290330A1 (en) 2017-06-22 2020-01-02 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
CN108530375B (zh) * 2018-05-29 2020-04-21 南京药石科技股份有限公司 4-氧杂-7-氮杂螺[2.5]辛烷或其盐的中间体及制备方法
CN113365664A (zh) 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
IL314677A (en) * 2022-02-16 2024-10-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Metap2 inhibitors and uses thereof
CA3261603A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd ANTIBODY-DRUG CONJUGATES
WO2024040009A2 (en) * 2022-08-17 2024-02-22 Primetime Life Sciences, Llc Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
CA1329771C (en) * 1988-09-01 1994-05-24 Shoji Kishimoto Angiogenesis inhibitory agent
EP0682020A1 (en) * 1988-09-01 1995-11-15 Takeda Chemical Industries, Ltd. Fumagillol derivatives useful as angiogenesis inhibitors
JPH0660168B2 (ja) * 1988-09-01 1994-08-10 武田薬品工業株式会社 ０―置換フマギロール誘導体
ATE87623T1 (de) * 1989-03-06 1993-04-15 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.

Also Published As

Publication number Publication date
IL91250A0 (en) 1990-03-19
US5789405A (en) 1998-08-04
FI893794L (fi) 1990-02-13
JPH08319281A (ja) 1996-12-03
EP0354787A1 (en) 1990-02-14
HU211569A9 (en) 1995-12-28
DE68921114D1 (de) 1995-03-23
KR900003164A (ko) 1990-03-23
DK390989A (da) 1990-02-13
AU632056B2 (en) 1992-12-17
US5767293A (en) 1998-06-16
FI97805B (fi) 1996-11-15
FI893794A0 (fi) 1989-08-11
DE68921114T2 (de) 1995-06-08
CA1340291C (en) 1998-12-29
IL91250A (en) 1994-10-21
NO893235D0 (no) 1989-08-11
JP2970524B2 (ja) 1999-11-02
ATE118490T1 (de) 1995-03-15
FI97805C (fi) 1997-02-25
EP0354787B1 (en) 1995-02-15
JPH0285272A (ja) 1990-03-26
KR0130765B1 (ko) 1998-04-09
JP2773275B2 (ja) 1998-07-09
DK390989D0 (da) 1989-08-09
GR3015382T3 (en) 1995-06-30
AU3945389A (en) 1990-02-15
DK171987B1 (da) 1997-09-08
CN1051703C (zh) 2000-04-26
NO173236C (no) 1993-11-17
ES2067546T3 (es) 1995-04-01
NO893235L (no) 1990-02-13
CN1079898A (zh) 1993-12-29
NO173236B (no) 1993-08-09
IE892505L (en) 1990-02-12
IE66923B1 (en) 1996-02-07

Similar Documents

Publication Publication Date Title
PH26256A (en) Oxaspiro [2,5] octane derivative
EP0354767B1 (en) Cyclohexane derivative
US6040337A (en) 5-demethoxyfumagillol derivatives and processes for preparing the same
CA2205384C (en) Dihydropyrimidines and uses thereof
EP0359036B1 (en) Fumagillol derivatives
US5164410A (en) Fumagillol derivatives and pharmaceutical compositions thereof
US5180738A (en) Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) Fumagillol derivatives and pharmaceutical compositions thereof
EP0539938A1 (en) Tri-substituted tetrahydrofuran antifungals
EP0357061A1 (en) Angiogenesis inhibitory agent
TASAKA et al. Optically active antifungal azoles. I. Synthesis and antifungal activity of (2R, 3R)-2-(2, 4-difluorophenyl)-3-mercapto-1-(1H-1, 2, 4-triazol-1-yl)-2-butanol and its stereoisomers
WO2003078438A1 (en) Carbamates as hiv protease inhibitors
EP0415294A2 (en) Cyclohexanol derivatives, production and use thereof
IT8224200A1 (it) Composti 1-ossa- aza- e tia-spirociclici ad attivita' analgesica
WO2000017162A1 (en) Novel thiol derivatives, process for producing the same and utilization thereof
Konosu et al. Triazole antifungals. III. Stereocontrolled synthesis of an optically active triazolylmethyloxirane precursor to antifungal oxazolidine derivatives
Jordis et al. Synthesis of (1R, 4R)-and (1S, 4S)-2, 5-diazabicyclo [2.2. 1] heptanes and their N-substituted derivatives
EP0510700A2 (en) Azole compounds, their production and use
RU2068412C1 (ru) Производное оксаспиро [2,5] октана и способ его получения (варианты)
KR102889453B1 (ko) Mdm2 억제제의 제조 방법
CN114981251A (zh) 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途